PT1919883E - N-óxidos como pró-medicamentos de derivados de piperazina & piperidina - Google Patents

N-óxidos como pró-medicamentos de derivados de piperazina & piperidina Download PDF

Info

Publication number
PT1919883E
PT1919883E PT06778284T PT06778284T PT1919883E PT 1919883 E PT1919883 E PT 1919883E PT 06778284 T PT06778284 T PT 06778284T PT 06778284 T PT06778284 T PT 06778284T PT 1919883 E PT1919883 E PT 1919883E
Authority
PT
Portugal
Prior art keywords
art
relates
disease
manufacture
disclosed
Prior art date
Application number
PT06778284T
Other languages
English (en)
Inventor
Roelof W Feenstra
Andrew C Mccreary
Mayke B Hesselink
Theodorus S M Koopman
Hendrik J Koster
Peter H Van Amsterdam
Marinus Verhage
Gustaaf J M Van Scharrenburg
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of PT1919883E publication Critical patent/PT1919883E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/24Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PT06778284T 2005-08-22 2006-08-21 N-óxidos como pró-medicamentos de derivados de piperazina & piperidina PT1919883E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70982105P 2005-08-22 2005-08-22
EP05107671 2005-08-22

Publications (1)

Publication Number Publication Date
PT1919883E true PT1919883E (pt) 2009-03-26

Family

ID=39246895

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06778284T PT1919883E (pt) 2005-08-22 2006-08-21 N-óxidos como pró-medicamentos de derivados de piperazina & piperidina

Country Status (17)

Country Link
EP (1) EP1919883B1 (pt)
JP (1) JP2009504799A (pt)
KR (1) KR20080046205A (pt)
AT (1) ATE417834T1 (pt)
AU (1) AU2006283882B2 (pt)
CA (1) CA2621158A1 (pt)
DE (1) DE602006004363D1 (pt)
DK (1) DK1919883T3 (pt)
ES (1) ES2318783T3 (pt)
HR (1) HRP20090143T3 (pt)
IL (1) IL188903A0 (pt)
NO (1) NO20081435L (pt)
PL (1) PL1919883T3 (pt)
PT (1) PT1919883E (pt)
RU (1) RU2394821C2 (pt)
SI (1) SI1919883T1 (pt)
WO (1) WO2007023141A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
MY148457A (en) * 2006-06-16 2013-04-30 Solvay Pharm Bv Combination preparations comprising slv308 and a dopamine agonist
EP2059244A1 (en) 2006-08-31 2009-05-20 Solvay Pharmaceuticals B.V. Titration schedule for bifeprunox for treating schizophrenia and kits for use therein
EP2146961B1 (en) * 2007-04-12 2014-01-29 IVAX International GmbH N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US20110105523A1 (en) * 2008-01-15 2011-05-05 Van Stuivenberg Herman H Bifeprunox derivatives
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
EA027748B1 (ru) 2012-04-04 2017-08-31 Тева Фармасьютикалз Интернэшнл Гмбх Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE503170A (pt) * 1975-09-02
DE69736704T2 (de) * 1996-03-29 2007-09-13 Duphar International Research B.V. Piperazin- und piperidin- derivate
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
HUP0302016A2 (hu) * 2000-05-12 2003-09-29 Solvay Pharmaceuticals B.V. Piperazin és piperidinvegyületek, ezeket tartalmazó gyógyászati készítmények, eljárás elżállításukra és alkalmazásuk
US20050085510A1 (en) * 2002-01-16 2005-04-21 Telefonaktiebolaget Lm Ericsson (Publ) Prucalopride-n-oxide

Also Published As

Publication number Publication date
DK1919883T3 (da) 2009-04-14
KR20080046205A (ko) 2008-05-26
ATE417834T1 (de) 2009-01-15
CA2621158A1 (en) 2007-03-01
EP1919883A1 (en) 2008-05-14
EP1919883B1 (en) 2008-12-17
PL1919883T3 (pl) 2009-06-30
RU2008110945A (ru) 2009-09-27
WO2007023141A1 (en) 2007-03-01
DE602006004363D1 (de) 2009-01-29
IL188903A0 (en) 2008-04-13
AU2006283882A1 (en) 2007-03-01
ES2318783T3 (es) 2009-05-01
HRP20090143T3 (en) 2009-04-30
RU2394821C2 (ru) 2010-07-20
SI1919883T1 (sl) 2009-04-30
AU2006283882B2 (en) 2011-06-23
NO20081435L (no) 2008-05-16
JP2009504799A (ja) 2009-02-05

Similar Documents

Publication Publication Date Title
HRP20090143T3 (en) N-oxides as prodrugs of piperazine&piperidine derivatives
TW200505907A (en) Piperidine-benzenesulfonamide derivatives
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20051826L (no) Heterosyklisk substituerte piperaziner for behandling av schizofreni
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
UA83899C2 (uk) Сполуки імідазолу для лікування нейродегенеративних розладів
ATE493407T1 (de) 3-(heteroaryloxy)-2-alkyl-1- azabicycloalkylderivate als alpha.7-nachr- liganden zur behandlung von zns-erkrankungen
WO2005079802A8 (en) Bipyridyl amides as modulators of metabotropic glutamate receptor-5
NO20060768L (no) 1-(2-amino-benzol)-piperazinderivater som glycinopptaks-inhibitorer for behandling av psykoser
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
ES2162257T3 (es) N-aminoalquildibenzofurancarboxamidas como ligandos especificos del subtipo de receptor de la dopamina.
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
NO20072046L (no) Halogensubstituerte benzodiazepinderivater
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
NO20072972L (no) Terapeutiske pyrazolo[3,4-B]pyridiner og indazoler
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
ZA200906573B (en) Dibenzo[1,4]oxazapine compounds
UA94718C2 (ru) N-оксиды в качестве пролекарств производных пиперазина и пиперидина
ATE496534T1 (de) Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden
UA96756C2 (en) N-oxides of pyridylmethylpiperazine and -piperidine derivatives
DE60307286D1 (de) Verfahren zur Herstellung von 2-Methyl Piperazine Derivaten.
BRPI0514077A (pt) derivados de benzilóxi como inibidores de maob
IL188109A0 (en) Chloro-substituted guanidines
MXPA06000193A (es) Derivados de imidazol iii.
DE69906728D1 (de) Verwendung von 4-piperidinmethanolderivaten zur behandlung von neuralentwicklungsstörungen